R&D
Technology to Increase Selectivity for
cancer cells and Enhance Efficacy
Pipeline
  • HOME
  • R&D
  • Pipeline
Pipeline Target Indication
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Small Molecule NTX-301 DNMT1 Blood Cancer (MDS/AML)
US - Single Agent (UAB)
Blood Cancer (T-ALL)
US - Single Agent (UAB)
Solid Tumor (MEN 1 Syndrome, etc.)
US - Single Agent (NCI)
Solid Tumor (Ovarian/Bladder)
AUS - Combi (SOCRU, etc.)
NTX-101 11β-HSD1 NAION, AAC, Glaucoma
KR - Single Agent (Inje Univ.)
PINOT- ADCTM PBX-001 Trop2 Triple-Negative Breast Cancer (TNBC) Bladder, Pancreatic Cancer, etc.
PBX-002 Undisclosed Triple-Negative Breast Cancer (TNBC)

Research Collaboration (KR)

PBX-003 EGFR Colorectal Cancer, Pancreatic Cancer Head and Neck Cancer w/K-ras mt.
PBX-004 FGFR2 Intrahepatic Cholangiocarcinoma Gastric Cancer